The use of viral vectors in vaccine development

Vaccines represent the single most cost-efficient and equitable way to combat and eradicate infectious diseases. While traditional licensed vaccines consist of either inactivated/attenuated versions of the entire pathogen or subunits of it, most novel experimental vaccines against emerging infectious diseases employ nucleic acids to produce the antigen of interest directly in vivo. These include DNA plasmid vaccines, mRNA vaccines, and recombinant viral vectors. The advantages of using nucleic acid vaccines include their ability to induce durable immune responses, high vaccine stability, and ease of large-scale manufacturing. In this review, we present an overview of pre-clinical and clinical data on recombinant viral vector vaccines and discuss the advantages and limitations of the different viral vector platforms.

Automated summary

Vaccines are the most cost-efficient and equitable way to combat and eradicate infectious diseases. Nucleic acid vaccines, including DNA plasmid vaccines, mRNA vaccines, and recombinant viral vectors, have advantages such as inducing durable immune responses, high vaccine stability, and ease of large-scale manufacturing. In this review, we provide an overview of pre-clinical and clinical data on recombinant viral vector vaccines and discuss the advantages and limitations of different viral vector platforms.